The heterogeneity of metabolic syndrome presentation and challenges this causes in its pharmacological management. A narrative review focusing on principal risk modifiers.

I have identified physiological, pathological, social and medical sources of phenotypical heterogeneity in the MetS and its constitutive traits. Improved understanding of these variables may be utilized in the setting of future precision medicine approaches in the field of metabolic disorders and target organ damage.